ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom
| IBRX Stock | USD 2.60 0.14 5.69% |
Slightly above 72 percent of all Immunitybio's investors are curious in acquiring. The analysis of the overall investor sentiment regarding Immunitybio suggests that a large number of traders are confidant. Immunitybio's investing sentiment can be driven by a variety of factors including economic data, Immunitybio's earnings reports, geopolitical events, and overall market trends.
Immunitybio | Build AI portfolio with Immunitybio Stock |
CULVER CITY, Calif., January 15, 2025--ImmunityBio, Inc. today announced the completion of the submissions of its marketing authorization applications for ANKTIVA plus Bacillus Calmette-Gurin for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ , with or without papillary tumors, to both the European Union European Medicines Agency and the United King
Read at finance.yahoo.com
 |
Immunitybio Maximum Pain Price Across August 15th 2025 Option Contracts
Immunitybio's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Immunitybio close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Immunitybio's options.
Immunitybio Fundamental Analysis
We analyze Immunitybio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunitybio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunitybio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
Immunitybio is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Immunitybio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immunitybio stock to make a market-neutral strategy. Peer analysis of Immunitybio could also be used in its relative valuation, which is a method of valuing Immunitybio by comparing valuation metrics with similar companies.
Peers
Immunitybio Related Equities
| VIR | Vir Biotechnology | 9.03 | ||||
| XFOR | X4 Pharmaceuticals | 8.31 | ||||
| CVAC | CureVac NV | 4.28 | ||||
| ELEV | Elevation Oncology | 3.33 | ||||
| BLRX | BioLineRx | 2.99 | ||||
| PLX | Protalix Biotherapeutics | 1.92 | ||||
| KRYS | Krystal Biotech | 1.82 | ||||
| TGTX | TG Therapeutics | 1.62 | ||||
| MCRB | Seres Therapeutics | 0.57 | ||||
| VKTX | Viking Therapeutics | 0.18 | ||||
| MDGL | Madrigal Pharmaceuticals | 0.35 | ||||
| ARDX | Ardelyx | 1.51 | ||||
| PDSB | PDS Biotechnology | 4.20 | ||||
| PPCB | Propanc Biopharma | 4.76 | ||||
| LXRX | Lexicon Pharmaceuticals | 5.71 |
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.